Immunogenicity and Safety of Group A, C, Y & W-135 Meningococcal Polysaccharide Diphtheria Toxoid Conjugate Vaccine

PHASE2CompletedINTERVENTIONAL
Enrollment

525

Participants

Timeline

Start Date

July 31, 2013

Primary Completion Date

May 31, 2014

Study Completion Date

December 31, 2014

Conditions
Meningococcal MeningitisMeningococcal Infections
Interventions
BIOLOGICAL

Test Vaccine

NmVac4-A/C/Y/W-135-DT™ conjugate is a vaccine in liquid form composed of purified polysaccharides (PS) conjugated to diphtheria toxoid. Single intramuscular 0.5 mL dose contains 4 µg each of Serogroup A, C, W-135, and Y PS conjugated to approximately 26 µg total diphtheria toxoid.

BIOLOGICAL

US Licensed Vaccine

Meningococcal (Groups A,C,Y,W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine 0.5 mL dose, intramuscular. Single dose contains 4 µg each Serogroup A, C, W-135 and Y conjugated to approximately 48 µg total diphtheria toxoid.

Trial Locations (3)

20770

Mid Atlantic Urology Associates LLC, Greenbelt

21122

Chesapeake Research Group, Pasadena

21204

IRC Clinics, Towson

All Listed Sponsors
lead

JN-International Medical Corporation

INDUSTRY